We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$486M 6.88%
8,249,873
-129,769
-2% -$7.22M
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$392M 5.54%
3,210,900
-48,574
-1% -$5.37M
INCY icon
3
Incyte
INCY
$23.4B
$342M 4.84%
3,292,600
-31,400
-0.9% -$3.03M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$285M 4.04%
982,600
-290,489
-23% -$78.8M
ESPR
5
DELISTED
Esperion Therapeutics
ESPR
$272M 3.85%
5,303,135
+265,245
+5% +$11.1M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$35.7B
$238M 3.37%
1,610,065
-165,199
-9% -$22.3M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.36B
$215M 3.05%
4,023,573
+118,129
+3% +$5.47M
ARGX icon
8
argenx
ARGX
$53.8B
$215M 3.04%
954,016
-20,488
-2% -$3.64M
MRNA icon
9
Moderna
MRNA
$24.5B
$215M 3.04%
3,344,950
-605,231
-15% -$33.1M
HALO icon
10
Halozyme
HALO
$9.23B
$180M 2.55%
6,730,552
-933,404
-12% -$21.1M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$159M 2.24%
1,412,828
+81,500
+6% +$8.65M
MGNX icon
12
MacroGenics
MGNX
$285M
$140M 1.98%
5,002,116
-1,117,034
-18% -$19.4M
ABT icon
13
Abbott
ABT
$175B
$117M 1.66%
1,284,272
– –
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$117M 1.65%
1,208,313
-103,400
-8% -$8.63M
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$97M 1.37%
3,779,919
+48,100
+1% +$974K
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
$95.8M 1.36%
4,647,000
-168,109
-3% -$2.29M
RDUS
17
DELISTED
Radius Health, Inc.
RDUS
$95.5M 1.35%
7,007,385
+24,000
+0.3% +$330K
BMY icon
18
Bristol-Myers Squibb
BMY
$124B
$94.8M 1.34%
1,612,112
+406,640
+34% +$24.3M
HUM icon
19
Humana
HUM
$48B
$91.4M 1.29%
235,640
+37,522
+19% +$14M
UNH icon
20
UnitedHealth
UNH
$387B
$90.4M 1.28%
306,636
-9,572
-3% -$2.74M
MDT icon
21
Medtronic
MDT
$106B
$89.6M 1.27%
977,523
+32,207
+3% +$3.09M
ISRG icon
22
Intuitive Surgical
ISRG
$122B
$89M 1.26%
468,699
-192,414
-29% -$34.5M
NKTR icon
23
Nektar Therapeutics
NKTR
$2.31B
$81.9M 1.16%
235,668
+3,354
+1% +$1.05M
ELV icon
24
Elevance Health
ELV
$80.9B
$81.5M 1.15%
310,025
-55,578
-15% -$14.8M
DHR icon
25
Danaher
DHR
$144B
$79.9M 1.13%
509,442
+119,739
+31% +$17.2M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.